1. Rah UW, Kim YH, Ohn SH, Chun MH, Kim MW, Yoo WK, et al. Clinical practice guideline for stroke rehabilitation in Korea 2012. Brain Neurorehabil. 2014; 7(Suppl 1):S1–S75.
Article
2. Francisco GE, Walker WC, Zasler ND, Bouffard MH. Pharmacological management of neurobehavioural sequelae of traumatic brain injury: a survey of current physiatric practice. Brain Inj. 2007; 21:1007–1014. PMID:
17891562.
Article
3. Sadowsky CH, Galvin JE. Guidelines for the management of cognitive and behavioral problems in dementia. J Am Board Fam Med. 2012; 25:350–366. PMID:
22570399.
Article
4. Liepert J. Update on pharmacotherapy for stroke and traumatic brain injury recovery during rehabilitation. Curr Opin Neurol. 2016; 29:700–705. PMID:
27748687.
Article
5. Gallacher KI, Batty GD, McLean G, Mercer SW, Guthrie B, May CR, et al. Stroke, multimorbidity and polypharmacy in a nationally representative sample of 1,424,378 patients in Scotland: implications for treatment burden. BMC Med. 2014; 12:151. PMID:
25280748.
Article
6. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomized controlled trials. Lancet Neurol. 2007; 6:782–792. PMID:
17689146.
7. Taverni JP, Seliger G, Lichtman SW. Donepezil medicated memory improvement in traumatic brain injury during post acute rehabilitation. Brain Inj. 1998; 12:77–80. PMID:
9483340.
8. Sivan M, Neumann V, Kent R, Stroud A, Bhakta BB. Pharmacotherapy for treatment of attention deficits after non-progressive acquired brain injury: a systematic review. Clin Rehabil. 2010; 24:110–121. PMID:
20103574.
Article
9. Whyte J, Hart T, Vaccaro M, Grieb-Neff P, Risser A, Polansky M, et al. Effects of methylphenidate on attention deficits after traumatic brain injury: a multi-dimensional, randomized, controlled trial. Am J Phys Med Rehabil. 2004; 83:401–420. PMID:
15166683.
10. Giacino JT, Whyte J, Bagiella E, Kalmar K, Childs N, Khademi A, et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med. 2012; 366:819–826. PMID:
22375973.
Article
11. Oyarzun-Gonzalez XA, Taylor KC, Myers SR, Muldoon SB, Baumgartner RN. Cognitive decline and polypharmacy in an elderly population. J Am Geriatr Soc. 2015; 63:397–399. PMID:
25688619.
Article
12. Collett GA, Song K, Jaramillo CA, Potter JS, Finley EP, Pugh MJ. Prevalence of central nervous system polypharmacy and associations with overdose and suicide-related behaviors in Iraq and Afghanistan war veterans in VA care 2010–2011. Drugs Real World Outcomes. 2016; 3:45–52.
Article
13. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014; 13:57–65. PMID:
24073682.
Article